Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eisai's Achievements Most Conspicuous in FY2011 Settlement of Accounts: Nomura Securities
June 13, 2011
- IMUC Becomes 18th Licensee for POTELLIGENT Technology: BioWa
June 13, 2011
- Kyowa Hakko Bio Establishes Efficient Amino Acid Derivative Manufacturing Process
June 13, 2011
- Teijin: Bonalon, Onealfa Contribute to Growth in Sales
June 13, 2011
- DSP to Inaugurate Global Oncology Business Development Office
June 13, 2011
- NanoCarrier's Micelle Technology Moves Closer to Patent in Japan
June 13, 2011
- Meiji HD: Pharmaceuticals Segment's Sales Up 2.3%
June 13, 2011
- JPMA to Issue Serious Warning against MSD over PC Violations
June 13, 2011
- OPC-34712's Promise as New Antipsychotic Confirmed in PII: Otsuka
June 13, 2011
- Yakult: Pharmaceutical Sales Up 10.8% Driven by Elplat
June 13, 2011
- Mirabegron Recommended for Approval for Treatment of OAB
June 13, 2011
- DSP, Kyorin Announce Results of Domestic PII Trial of Ranirestat
June 13, 2011
- Ajinomoto: Pharma Operating Profits Down 32% due to Higher R&D Costs
June 13, 2011
- Korosho to Conduct Survey on Economic Conditions in Healthcare
June 13, 2011
- KW-6002 Found Effective for PD in Domestic PIII Study: Kyowa Kirin
June 13, 2011
- Asahi Kasei Pharma: Sales Up 3.4% Driven by 3.5-Fold Increase in Sales of Recomodulin
June 13, 2011
- Council to Discuss Revision of Copayments for OTC-like Drugs
June 13, 2011
- JAK Inhibitor Tofacitinib Reduces Symptoms of RA: Pfizer Inc.
June 13, 2011
- ASKA: First Net Loss since Merger due to Earthquake
June 13, 2011
- Industry FTC Revises GL on Business Entertainment Practices
June 13, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…